XTalks

FEBRUARY 5, 2024

It is prescribed for the treatment of metastatic breast cancer in patients with HR-positive/HER2-negative status. Novartis attributed the growth to increased recognition of the drug’s life-extension benefit in metastatic breast cancer. Price of Verzenio: The list price of Verzenio is $15,405.72 For Kisqali, sales reached $1.5

FDA Approval 101

FDA Approval Drugs Sales Development 101

XTalks

FEBRUARY 5, 2024

It is prescribed for the treatment of metastatic breast cancer in patients with HR-positive/HER2-negative status. Novartis attributed the growth to increased recognition of the drug’s life-extension benefit in metastatic breast cancer. Price of Verzenio: The list price of Verzenio is $15,405.72 For Kisqali, sales reached $1.5

FDA Approval 52

FDA Approval Drugs Sales Development 52

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. Stelara’s patents are expiring in September 2023, while a handful of biosimilar drugs are in late-stage development or seeking FDA approval.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

MAY 4, 2021

In February 2021, Pfizer and BioNTech announced results from an in vitro study published in NEJM that demonstrated sera from individuals immunized with BNT162b2 neutralize SARS-CoV-2 with the South African variant spike protein. The study investigated the full set of South African variant (also known as B.1.351

Vaccination 40

Vaccination Vaccine Production Sales 40